Loading
Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.
Andrea Sartore-Bianchi is a medical oncologist at the Niguarda Cancer Center in Milan. He was first author of the 2016 Lancet Oncology report of HERACLES, the phase 2 trial in which trastuzumab plus lapatinib produced responses in about a third of patients with heavily pretreated HER2-amplified, KRAS wild-type metastatic colorectal cancer, establishing HER2 as a target in the disease. His research covers resistance to anti-EGFR antibodies and molecular selection for therapy.
| Title | Journal | Year |
|---|---|---|
| HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer | The Lancet Oncology | 2016 |
The first demonstration that HER2 is actionable in colorectal cancer, and the trial that defined the colorectal-specific HER2 scoring criteria every later trial has used.
It is the threshold behind the colorectal HER2 approvals: the more-than-50% rule, rather than the 10% used in gastric cancer, is what a pathologist applies when a bowel cancer is called HER2-positive.
It made acquired resistance a measurable, plasma-readable event, and it is the origin of anti-EGFR rechallenge strategies guided by ctDNA clearance of the resistant clone.
Shares Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, HERACLES, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study and the tags colorectal, targeted-therapy, trialist.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer and the tag colorectal.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.